This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Arena Pharmaceuticals(ARNA - Get Report) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors. This stock, which is
rated D- sell by TheStreet Ratings, is trading up 10.9% at $1.78 in recent trading.
Today's Range: $1.70-$1.86
52-Week Range: $1.21-$2.62
Volume: 4.9 million
Three-Month Average Volume: 1.85 million
Shares of ARNA are jumping higher today after the U.S. Food and Drug Administration said it has accepted its resubmitted application for the diet-drug Lorcaserin. The FDA is expected to decide on whether to approve the drug by June 27.
technical standpoint, ARNA is soaring back above its 50-day moving average of $1.67 today on huge volume. Market players should continue to look for long biased trades as long as ARNA closes above the 50-day and near its daily high of $1.86.
If we get that action, look for ARNA to challenge $1.90 to $2 in the near future as long as the upside
volume continues to track in strong. Any future move above $2.15 should then set this stock up to re-test its December high of $2.62.